SEC Probes Aveo Over Failed Renal Cancer Drug

Law360, New York (July 12, 2013, 7:42 PM ET) -- Aveo Pharmaceuticals Inc. on Thursday said the U.S. Securities and Exchange Commission has launched a probe in connection with the drugmaker’s experimental kidney cancer drug, which in June was rejected by the U.S. Food and Drug Administration.

The Cambridge, Mass.-based company said it received a subpoena from the SEC on July 3 requesting documents and information concerning tivozanib, which the FDA in June declined to approve for the treatment of patients with advanced renal cell carcinoma.

Aveo said the SEC requested tivozanib-related communications with the FDA,...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required